國家衛生研究院 NHRI:Item 3990099045/6885

NHRI > National Institute of Infectious Diseases and Vaccinology > Chia-Chyi Liu > Periodical Articles > Item 3990099045/6885

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/6885

Title:	Immunological and biochemical characterization of Coxsackie Virus A16 viral particles
Authors:	Chong, P;Guo, MS;Lin, FHY;Hsiao, KN;Weng, SY;Chou, AH;Wang, JR;Hsieh, SY;Su, IJ;Liu, CC
Contributors:	Division of Vaccine Research and Development;Division of Infectious Diseases
Abstract:	Background: Coxsackie virus A16 (CVA16) infections have become a serious public health problem in the Asia-Pacific region. It manifests most often in childhood exanthema, commonly known as hand-foot-and-mouth disease (HFMD). There are currently no vaccine or effective medical treatments available. Principal Finding: In this study, we describe the production, purification and characterization of CVA16 virus produced from Vero cells grown on 5 g/L Cytodex 1 microcarrier beads in a five-liter serum-free bioreactor system. The viral titer was found to be >106 the tissue culture's infectious dose (TCID50) per mL within 7 days post-infection when a multiplicity of infection (MOI) of 10?5 was used for initial infection. Two CVA16 virus fractions were separated and detected when the harvested CVA16 viral concentrate was purified by a sucrose gradient zonal ultracentrifugation. The viral particles detected in the 24–28% sucrose fractions had low viral infectivity and RNA content. The viral particles obtained from 35–38% sucrose fractions were found to have high viral infectivity and RNA content, and composed of four viral proteins (VP1, VP2, VP3 and VP4), as shown by SDS-PAGE analyses. These two virus fractions were formalin-inactivated and only the infectious particle fraction was found to be capable of inducing CVA16-specific neutralizing antibody responses in both mouse and rabbit immunogenicity studies. But these antisera failed to neutralize enterovirus 71. In addition, rabbit antisera did not react with any peptides derived from CVA16 capsid proteins. Mouse antisera recognized a single linear immunodominant epitope of VP3 corresponding to residues 176–190. Conclusion: These results provide important information for cell-based CVA16 vaccine development. To eliminate HFMD, a bivalent EV71/CVA16 vaccine formulation is necessary.
Date:	2012-11-30
Relation:	PLoS ONE. 2012 Nov 30;7(11):Article number e49973.
Link to:	http://dx.doi.org/10.1371/journal.pone.0049973
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1932-6203&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000312376100041
Cited Times(Scopus):	http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84870600954
Appears in Collections:	[Chia-Chyi Liu] Periodical Articles [Pele Choi-Sing Chong] Periodical Articles [Ih-Jen Su(2002-2015)] Periodical Articles

Files in This Item:

File	Description	Size	Format
PLO2012120109.pdf		1696Kb	Adobe PDF	595	View/Open

Loading...